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Antimicrobial propertiesAbstract We report new reaction conditions (less corrosive reagents) for the regio-speciﬁc synthe-
sis, spectroscopic properties, crystal structure, antimicrobial activities and MICs of 1-methyl-4-
nitro-1H-imidazole (I). For structure conﬁrmation, X-ray crystallography was performed using
crystals obtained from chloroform and hexane (1:1). The structure of the compound (I) was further
characterized by FTIR, 1H NMR, 13C NMR and EIMS. Important peaks appearing in the EIMS,
at the m/z= 127, 111, 97, 81, and 54 arise due to the loss of single electron, loss of O, NO, NO2,
and loss of NO2 & HCN respectively. The high intensity peak in the EIMS at m/z= 42 arises due to
the loss of NO, CO and HCN from the molecular ion. The correct 1H NMR (400 MHz, CDCl3) of
(I) shows peaks at 7.76 (ArH, HC‚N), 7.42 (ArH, HC‚C), and 3.82 (N–CH3) ppm. Further struc-
tural studies showed that the driving force for crystallization (self-assembly) and hydrogen bonding
(C–H. . .O–NO, 2.57 A˚) originates from the partial negative oxygen of the nitro (NO2) group at one
end and the partial positive hydrogen (N–CH3) at another corner of the molecule. Biological assay
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Antimicrobial activities of 1-methyl-4-nitro-1H-imidazole 669against many (13) microorganisms and fungi showed that the title compound (I) is moderately
active against Gram (+), Gram () bacteria and fungi.
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an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Nitration is one of the earliest known, important reactions in
organic chemistry (Schoﬁeld and Swain, 1948). The reaction
can be carried out with different nitrating agents, depending
on the substrate and reaction conditions to obtain C–NO2,
O–NO2 and N–NO2 functionalized compounds (Katritzky
et al., 2005a,b). However, Electrophilic Nitration (C–NO2) of
heterocyclic compounds holds higher importance in medicinal
organic chemistry (McCalla et al., 1971; Baumann et al., 2011).
Heterocyclic compounds containing the nitro group are
well recognized for antibacterial activities and synthesis of
other biologically and industrially valuable active compounds
(Bollo et al., 2004). Nitroimidazole is a class of heterocyclic
compounds known as antibacterial agents for a long time
(Cosar and Julou, 1959; Anthwal et al., 2013; Anderson
et al., 2012) due to its broad spectrum against Gram positive
and Gram negative bacteria and other organisms (Edwards,
1993). Similarly, the 4-nitro derivatives of 1-alkyl-1H-imidaz-
ole are well known as active pharmaceutical intermediates
(APIs) for example, immunodepressant Azathioprine drug
(Yrowell and Elion, 1973), preparation of 4 aminoimidazole
derivatives as the inhibitors of cyclin-dependent kinase 5/p25
for treatment of pain, stroke, Alzheimer’s disease, treatmentN
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compound (I).of type-II diabetes (Helal et al., 2009), and for synthesis of
various novel APIs as Janus-Associate Kinase (JAK) inhibi-
tors for treatment of cancer and myeloproliferative disorders
(Chuaqui et al., 2010; Pardanani et al., 2009; Abdel-Magid,
2012). The nitroimidazole and its derivatives have been widely
used by the medical community for various ailments, which is
a driving force for further exploration, and a more effective
pharmaceutical candidate for treatment of infectious diseases.
1-Methyl-4-nitro-1H-imidazole (compound (I), CAS: 3034-
41-1) is not provided by the standard large chemical suppliers
such as TCI, Aldrich, Acros, Alfa Aesar, etc. There are 2
important methods (Katritzky et al., 2005a,b; Duddu et al.,
2011) to prepare compound (I). For nitration, the ﬁrst method
(Katritzky et al., 2005a,b) uses triﬂuoroacetic anhydride/conc.
HNO3 at 0–5 C to give compound (I) in 39% yield as reported
in Section 4 (Scheme 1). This manuscript provided 1H NMR,
13C NMR, elemental analysis and melting point data with an
error in the 1H NMR data.
The second method (Scheme 1) (Duddu et al., 2011) uses
Fuming H2SO4/Fum. HNO3 at 0–15 C and provided com-
pound (I) in 46.8% yield (calculated (78:22) from total mixture
yield 60%). This yield is only based on 1H NMR analysis and
the 1H NMR data, spectra or any other characterization is
absent in the manuscript or the supporting information.
Further, the mixture was not isolated, which clearly shows difﬁ-
culties in separation. The authors also tried higher (110–120 C)
temperatures which resulted in the formation of 5 kinds of nitro
products (Scheme 1). Again the products were not isolated and
yields are only based on 1H NMR analysis (Duddu et al., 2011).
These two methods (Katritzky et al., 2005a,b; Duddu et al.,
2011) used well-known, hazardous materials such as triﬂuoro-
acetic anhydride, fuming H2SO4 and fuming HNO3. Some
researchers may believe that conc. H2SO4 (as used in our
research) and fuming H2SO4 (as used by other researchers)
are equally hazardous, but this is not true. This can be con-
ﬁrmed by the standard safety information (Aldrich) which
states that fuming H2SO4 containing only 20% SO3 (CAS:
8014-95-7, product code: 435597) has the double hazard codes
namely GHS05 (Corrosive to metals, category 1), and GHS06
(Acute toxicity (oral, dermal, inhalation), categories 1,2,3)
while 99.9% conc. H2SO4 (CAS: 7664-93-9, product code:
339741) shows single hazard code namely GHS05 (Corrosive
to metals, category 1). Similarly, common HNO3 (70%,
CAS: 7697-37-2, product code: 438073) shows safety codes
GHS03 (Oxidizing gases, category 1), GHS05 (Corrosive to
metals, category 1) while fuming HNO3 (90%, CAS: 7697-
37-2, product code: 309079) shows 3 safety codes GHS03
(Oxidizing gases, category 1), GHS05 (Corrosive to metals,
category 1), and GHS06 (Acute toxicity (oral, dermal, inhala-
tion), categories 1,2,3). Similarly we can ﬁnd that triﬂuoroace-
tic anhydride (99%, CAS: 407-25-0, product code: 106232)
shows 2 safety codes GHS05 (Corrosive to metals, category
1) and GHS07 (Acute toxicity (oral, dermal, inhalation),
category 4). Besides the toxicity of fuming H2SO4 and fuming
670 H.A. Shahid et al.HNO3, they contain sulphur and nitrogen oxides, responsible
for global acidiﬁcation and air pollution (Kikuchi, 2001). All
this information is sufﬁcient to prove that the reactions
performed in 99.99% conc. H2SO4 or common HNO3 are rel-
atively safer and environmentally friendly compared to those
performed in triﬂuoroacetic anhydride, fuming H2SO4 and
fuming HNO3 due to their acute toxicity and other effects. If
the synthesis methods based on more corrosive reagents are
applied on an industrial scale, then extraordinary protection
measures should be taken for humans and the environment.
The other disadvantage of these methods is that they produce
mixture of regio-isomeric products. When isomeric products
are obtained, they must be separated through column chroma-
tography which increases production cost. Therefore, more
environment friendly reaction conditions, giving single or
mainly one regio-isomer are highly desirable.
To best of our knowledge, we are the ﬁrst to report the
regio-speciﬁc synthesis under less corrosive reagent conditions,
unique crystal structure, structural properties, a small typo
correction in the 1H NMR data, and Biological assay against
13 microorganisms and fungi. Herein we report our results.Figure 1 ORTEP diagram of compound (I) with displacement
ellipsoids drawn at 50% probability level.2. Result and discussion
2.1. Synthesis and spectroscopic properties
Method A shows that 1-methyl-1H-imidazole can undergo
nitration in a mixed acid (non fuming) 98% H2SO4 (non-
fuming) and 65% HNO3 at 5–65 C bath temperature for 8 h.
Instead of isomers or mixture of products we obtained only sin-
gle regio-isomer namely 1-methyl-4-nitro-1H-imidazole in 20%
yield as shown in Scheme 1. Temperature control and slow addi-
tion are important factors to obtain regio-speciﬁc nitration.
Method B shows that 1-methyl-1H-imidazole can undergo
nitration in a mixture of urea nitrate/non-fuming conc.
H2SO4 (98%). The method eliminates the use of liquid
HNO3 as the source for nitronium ion, and uses urea nitrate
as an easy to handle source for nitration. Urea nitrate is known
to convert deactivated aromatic compounds to the correspond-
ing nitro derivatives with high regio-selectivity under mild con-
ditions (Almog et al., 2006) but so far it has not been applied
to make 1-methyl-4-nitro-1H-imidazole. The nitration process
for the 1-methyl-1H-imidazole happens at low temperatures
(10 to +10 C), so there is much less chance for non-regio-
speciﬁc nitration. In addition the method gives better yield
compared to Method A.
Spectroscopy such as, FTIR (Fig. SEI-1 and Table SEI-1),
EIMS (Fig. SEI-2 and Scheme SEI-1), 1H NMR (Fig. SEI-3),
13C NMR (Fig. SEI-4), and X-ray crystallography (Figs. 1 and
2) conﬁrmed that the product is 1-methyl-4-nitro-1H-imidaz-
ole. FTIR spectrum data of compound (I) is compared
(Table SEI-1) with the FTIR data (Acros Chemicals) of the
starting material, which shows clear nitration of 1-methyl-
1H-imidazole. EIMS spectrum (Fig. SEI-2) and clean fragmen-
tation pattern of compound (I) are well explained
(Scheme SEI-1). Important peaks appearing in the EIMS, at
the m/z= 127, 111, 97, 81, and 54 arise due to the loss of sin-
gle electron, loss of O, NO, NO2, and loss of NO2 & HCN
respectively. The high intensity peak at m/z= 42 arises due
to the loss of NO, CO and HCN from the molecular ion
(Luijten and Thuijl, 1981).1H NMR of compound (I) showed 3 peaks at d: 3.82, 7.42,
and 7.76 ppm corresponding to CH3, and two ArHs. We found
that compound (I) shows 1H NMR (400 MHz, CDCl3) peaks
at 7.76 (ArH, HC‚N), 7.42 (ArH, HC‚C), and 3.82 (N–
CH3) ppm instead of a previously reported (Katritzky et al.,
2005a,b) 1H NMR (300 MHz, CDCl3) 7.78 (ArH), 4.72
(ArH), and 3.83 (N–CH3) ppm. This might be a small correc-
tion of the printing error or typo but it is useful for future
research. 13C NMR showed 4 peaks at d: 34.6 ppm for CH3,
120.1 for ArCH (HC‚C), 136.6 for ArCH (HC‚N), and
148.3 ppm for the ArC–NO2 conﬁrming the product com-
pound (I).
2.2. X-ray crystallography
Single-crystal X-ray diffraction analysis was carried out to
conﬁrm the regio-speciﬁc nitration of the title compound (I).
Crystal structure in our case is of very high importance to rule
out the possibility of any other regio-isomer of compound (I).
Crystal structure shows that compound (I) is composed of
nitro and methyl groups attached to a planer imidazole ring.
A detailed analysis of the molecule (Fig. 1) shows that all
the bond lengths and angles are within expected ranges
(Allen et al., 1987). The crystal structure is stabilized by the
intermolecular hydrogen bonds (C–H  O–NO, 2.57 A˚) and
molecules are linked together to form sheets via C1—
H1A  O2 running in a zig-zag fashion parallel to the a-axis
(Fig. 2). Crystallographic data for structure determination
and reﬁnement of compound (I) are presented in Table 1.
CCDC 875050 contains supplementary crystallographic data
for compound (I). Data can be obtained free of charge via
http://www.ccdc.cam.ac.uk/cgi-bin/catreq.cgi, or from the
Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail:
deposit@ccdc.cam.ac.uk.
2.3. Structural properties
Properties of condensed phases are governed by the properties
of the individual molecules due to intermolecular forces
between molecules arising from electrostatic interactions
(Buckingham, 1978). To probe into the structural properties
of the 1-methyl-4-nitro-1H-imidazole or compound (I) we ﬁrst
optimized its molecular structure using Becke’s three-parame-
ter density functional theory (DFT) in combination with Lee–
Yang–Parr’s correlation functional (B3LYP) and employed
Figure 2 Crystal packing of compound (I); some hydrogen
atoms were omitted for clarity.
Figure 3 Top view of the optimized structure (a), side view (b)
and Mulliken charges (c) of the 1-methyl-4-nitro-1H-imidazole.
Antimicrobial activities of 1-methyl-4-nitro-1H-imidazole 6716-31G(d) basis sets (Lee et al., 1988; Becke, 1993) within the
Wavefunction Spartan 08 (Yamada et al., 2011).
Fig. 3a shows the top view of the optimized structure show-
ing corresponding atomic symbols. The side view (Fig. 3b) of
the optimized molecular structure shows that 1-methyl-4-
nitro-1H-imidazole is a planar molecule except the methyl
group (N–CH3) due to sp
3 hybridization. This observation is
consistent with its crystal structure (Fig. 1).
Fig. 3c shows the Mulliken charges (Mulliken, 1955;
Astrand et al., 1998) of different atoms in the optimizedTable 1 Crystal data and structure reﬁnement of compound
(I).
Empirical formula C4H5N3O2
Formula weight 127.11
Temperature (K) 273 (2)
Wavelength (A˚) 0.7103
Crystal system monoclinic
Space group P21/c
Unit cell dimensions
a (A˚) 5.8223(15)
b (A˚) 14.882(4)
c (A˚) 6.5873(18)
a () 90
b () 94.705(7)
c () 90
Volume (A˚3) 568.9(3)
Z 4
Calculated density (mg/m3) 1.484
Absorption coeﬃcient (mm1) 0.71073
Maximum and minimum
transmissions
0.9976 and 0.9417
F (000) 264
Crystal size (mm3) 0.50 · 0.10 · 0.02
Theta ranges for data
collection ()
2.74–25.5
Limiting indices 6 6 h 6 7, 18 6 k 6 17,
7 6 1 6 7
Reﬂections collected/ unique 3280/1048 [Rint = 0.0350]
Final R indices [I> 2r(I)] R1 = 0.0470, wR2 = 0.1188
R indices (all data) R1 = 0.0691, wR2 = 0.1337
Goodness-of-ﬁt on F2 1.023
Largest diﬀerence peak
and hole (e A˚3)
0.170 and 0.195molecular structure. The nitro group shows the partial positive
nitrogen (0.35) and partial negative oxygen atoms (0.41 and
0.38) which make one end of the molecule partial negativeFigure 4 Proposed crystallization process for 1-methyl-4-nitro-
1H-imidazole.
Figure 5 Anti-bacterial mechanism of nitroimidazole.
672 H.A. Shahid et al.(d) as shown in Fig. 3b. The nitrogen and carbon (N–CH3)
atoms showed partial negative charges (0.38 and 0.33
respectively) while the hydrogen (N–CH3) atoms showed
partial positive charge (0.19 each), which makes the second
corner of the molecule partially positive (d+) as shown in
Fig. 3b. The phenomenon of negative and positive polariza-
tions created the driving force (Fig. 4) for crystallization and
hydrogen bonding between the negatively charged oxygen
atom of the nitro (NO2) group and the positively charged
hydrogen atom (Figs. 3b and 2) of the methyl group (N–
CH3). This observation also explains the special orientation
of molecules in the crystal structure (Fig. 4). It can be observed
from the crystal structure that only one oxygen atom of the
nitro (NO2) group participates in the H-bonding (Fig. 2), likely
due to the more partial negative (0.41 vs. 0.38) charge of
one of the oxygen atoms bonded to NO2.
2.4. Biological assay
For nitro-imidazoles two mechanisms of action based on
previous studies have been reported (Van Der Wouden et al.,
2000). Nitroimidazole enters the cell by passive diffusion,
and is metabolized by a reduction step in which the drug
behaves as the electron acceptor. For this reduction step
several nitroreductases are present in Helicobacter pylori (bac-
teria). It has been suggested that an oxygen-insensitive
NADPH nitroreductase encoded by the rdxA gene is the most
important. Oxygen-insensitivity denotes in this case that the
reduction of the nitroimidazole (Ar–NO2) results in a nitroso-
derivate (Ar–NO) by the simultaneous transfer of two elec-
trons. This nitrosoderivate cannot be re-oxidized byTable 2 Antibacterial and antifungal activities of the title compoun
Gram positive bacteria Zone of
inhibition (mm)
mean ± S.D.
Gram negative
bacteria
Micrococcus luteus ATCC 9341 16 ± 1 Proteus mirabilis
Staphylococcus aureus 16 ± 0.6 Pseudomonas aerugin
Staphylococcus aureus AB 188 18 ± 0.6 Pseudomonas
aeruginosa ATCC
Proteus vulgaris
Morganella morganimolecular oxygen and the nitroreductase facilitating the two-
electron transfer step is therefore called oxygen-insensitive.
The nitrosoderivate leads to DNA damage and subsequent cell
death of bacteria (Fig. 5, Mechanism #1).
The second mechanism explains that the other nitroreducta-
ses present in H. pylori reduce a nitroimidazole (R–NO2) by a
one-electron transfer step to a toxic free radical anion (R–
NO2)
 that can be metabolized in two ways (Fig. 5, Mecha-
nism #2). First, the free-radical anion can be re-oxidized to
the original compound (R–NO2) by molecular oxygen with
the production of superoxide (O2
). Since molecular oxygen
may reverse the reduction step these nitroreductases are called
oxygen-sensitive. Theoretically, this process of reduction and
re-oxidation is repeated endlessly and is called ‘futile cycling’.
The superoxide produced during this ‘futile cycling’ is also
toxic but can be eliminated (conversion to water) by superox-
ide dismutase (SOD) and catalase. The second way to metab-
olize the toxic free radical anion is another one electron
transfer step to the more toxic nitrosoderivate that leads to
DNA damage (inhibiting bacterial nucleic acid synthesis) and
results in subsequent bacterial cell death of bacteria.
We have compared (as reference) the results with the stan-
dard drugs. For the antibacterial activity, we have used the
gentamicin drug and for the antifungal, we have used the gris-
eofulvin antifungal agent to draw meaningful comparison, the
tables in the manuscript were generated considering all these
parameters. This is a preliminary screening. We found encour-
aging results that the compound is active against pathogens.
Antimicrobial activities show that the title compound is mod-
erately active towards antibacterial and antifungal activities.
Antimicrobial results for the title compound (I) and minimum
inhibitory concentrations (MICs) for the bacterial and fungal
isolates are reported in Tables 2 and 3 and the range is 180–
300 lg/mL. Inhibition zones for Gram positive bacteria, Gram
negative bacterial and fungal isolates were in the range of 16–
18, 13–17 and 15–18 mm respectively. The maximum zone of
inhibition was observed for Gram positive bacteria on Staph-
ylococcus aureus AB 188 and for fungal isolate Candida tropi-
calis while 13 mm for Proteus mirabilis and Pseudomonas
aeruginosa, 15 mm for Morganella morganii, Candida glabrata
and Candida krusei, 16 mm for Micrococcus luteus ATCC
9341, S. aureus and Candida albicans ATCC 0383 and
17 mm for P. aeruginosa ATCC, Proteus vulgaris and C. albi-
cans. In summary, antimicrobial results indicate that the title
compound has the potential to kill some of the highly patho-
genic bacterial and fungal species that have a critical role in
a wide range of cutaneous, pyogenic and urinary tract infec-
tions (Gunay et al., 1999; Foroumadia et al., 2009).d by Agar well method.
Zone of inhibition
(mm) mean ± S.D.
Fungal isolates Zone of inhibition
(mm) mean ± S.D.
13 ± 1.5 Candida albicans 17 ± 1.2
osa 13 ± 2.1 Candida albicans
ATCC 0383
16 ± 1.5
17 ± 1 Candida glabrata 15 ± 2.1
17 ± 0.6 Candida tropicalis 18 ± 1.0
i 15 ± 0 Candida krusei 15 ± 0.6
Table 3 Minimum inhibitory concentration (MIC) of the title compound determined by micro-dilution method.
Gram positive bacteria MIC
lg/mL
Gram negative bacteria MIC lg/mL Fungal isolates MIC
lg/mL
Micrococcus luteus ATCC 9341 180 Proteus mirabilis 100 Candida albicans 240
Staphylococcus aureus 220 Pseudomonas aeruginosa 120 Candida albicans ATCC 0383 300
Staphylococcus aureus AB 188 220 Pseudomonas aeruginosa ATCC 100 Candida glabrata 180
Proteus vulgaris 280 Candida tropicalis –
Morganella morganii 200 Candida krusei 200
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In summary, we report two new reaction conditions for the
regio-speciﬁc synthesis of 1-methyl-4-nitro-1H-imidazole. We
have presented a complete characterization by using EIMS,
FTIR, 1HNMR, 13CNMR, and single crystal X-ray diffraction
analyses. The synthesis methods have the advantages of regio-
speciﬁcity, easy puriﬁcation and use of less corrosive reagents.
The important peaks appearing in EIMS, at m/z= 127, 111,
97, 81, and 54 arise due to the loss of single electron, loss of O,
NO, NO2, and loss of NO2 &HCN respectively. The high inten-
sity peak atm/z= 42 arises due to the loss ofNO, CO andHCN
from the molecular ion. We found that the title compound
shows 1H NMR (d, 400 MHz, CDCl3) peaks at 7.76 (ArH),
7.42 (ArH), and 3.82 (N–CH3) ppm. The crystal structure of
compound (I) is stabilized by the intermolecular hydrogen
bonds (C–H  O–NO, 2.57 A˚) andmolecules are linked to form
sheets in a zig-zag manner, but all the NO2 groups are headed in
one direction. This unique mode of crystallization is clearly
explained throughDFTbased structural properties. Compound
(I) was found to be moderately active for the antibacterial and
antifungal activities and maximum inhibition was examined
for Gram positive bacteria on S. aureus AB 188 and fungal iso-
late C. tropicalis while the MICs of the title compound lie in the
range of 180–300 lg/mL (observed concentration, at which
micro-organisms growth was inhibited). Antimicrobial results
indicate that compound (I) has the potential to kill some of
the highly pathogenic bacterial and fungal species playing criti-
cal role in a wide range of cutaneous, pyogenic and urinary tract
infections (Gunay et al., 1999; Foroumadia et al., 2009).
4. Experimental section
4.1. Materials and methods
All chemicals and solvents were of reagent grade and
purchased from Aldrich and used without further puriﬁcation.
Thin layer chromatography was performed on Merck silica gel
60F254 plates and observed under UV. Melting point (uncor-
rected) was recorded in a glass capillary tube on Gallenkamp
(sonyo) apparatus. FTIR spectra were recorded directly on
Bruker FTIR spectrophotometer (Vector 22) in the range of
4000–400 cm1. EIMS spectra were recorded on JeolMS
Route. 1H NMR recorded on BrukerAvance 400 and 13C
NMR recorded on BrukerAvance 300 spectrophotometers at
400 and 75 MHz respectively.
4.2. X-ray measurements
Single-crystal X-ray diffraction data were collected on Bruker
Smart APEX II, CCD 4-K area detector diffractometer(Siemens, 1996). Data reduction was performed using SAINT
program. The structure was solved by direct method
(Altomare et al., 1993) and reﬁned by full-matrix least squares
on F2 by using SHELXTL-PC package (Sheldrick, 1997). The
ﬁgures were plotted with ORTEP program (Johnson, 1976).
4.3. Synthesis of compound (I)
Nitrating Mixture: Inside hood, nitrating mixture was
prepared by mixing 4 mL of non-fuming H2SO4 (98%) and
3.8 mL of non-fuming HNO3 (65%) in a round bottom ﬂask
with continuous stirring. HNO3 was added slowly with the
help of a dropping funnel into H2SO4 to maintain the temper-
ature at 35–40 C.
4.4. Synthesis methods for 1-methyl-4-nitro-1H-imidazole
Method A: Inside hood, to a round bottom ﬂask ﬁtted with a
reﬂux condenser, was added nitrating mixture (7.8 mL) and the
mixture was cooled down to 5–7 C in an ice-salt cooled water-
bath. To the cooled nitrating mixture drop-wise was added 1-
methyl-1H-imidazole (1.019 g, 12.42 mmol) with continuous
stirring. After 0.5 h of addition; bath temperature was allowed
to increase temperature (60–65 C) for 8 h. After this time, the
reaction mixture was allowed to cool down to room tempera-
ture and the reaction mixture was added to a beaker contain-
ing puriﬁed water with stirrer. Mixture was transferred to a
separatory funnel and methylene chloride (CH2Cl2) was added
(50 mL · 3) to separate the organic phase. The organic phase
was dried on anhydrous Na2SO4 and ﬁltered. The CH2Cl2
was removed by rotary evaporator to afford the off-white
solid, which is recrystallized with a small amount of CH2Cl2
to give the title compound (I) in 20% yield.
Method B: Inside hood, to a 200 mL round bottom ﬂask
precooled to 10 C, freshly prepared dry solid 2.5 g
(20.31 mmol) urea nitrate (Shead, 1967) was added in small
portions to the liquid 1-methyl-1H-imidazole (1.019 g,
12.42 mmol, density= 1.03 g/cm3) and H2SO4 (15 mL). After
the complete addition, the temperature was slowly allowed
to increase up to 10 C and maintained for 6 h. The mixture
was then poured into a beaker containing crushed ice made
from distilled water. After the complete melt down, the acidic
solution was neutralized by aqueous Na2CO3 solution. The
organic phase was separated with EtOAc and ﬁltered through
a small plug of dry silica and Na2SO4 in a Buchner funnel.
EtOAc was used to wash silica and Na2SO4, and the solvent
was removed to obtain pure product. This process afforded
the off-white title compound (I) in 45% yield.
High quality single crystals suitable for X-ray crystallogra-
phy were grown in a mixture of solvents chloroform and
hexane (1:1) by slow evaporation at room temperature; mp:
674 H.A. Shahid et al.133–134 C. FTIR (KBr, cm1): v 3115 (‚C–H arom. str.),
2925 (C–H aliphatic str.), 1424 (C‚C ring str.), 1525, 1321
(NO2 Asym./Sym. str.), 982 (C–N).
1H NMR (400 MHz,
CDCl3, d, ppm): 3.82 (s, 3H, CH3), 7.42 (s, 1H, ArH, HC‚C),
7.76 (d, J= 1.0 Hz, 1H, ArH, HC‚N). 13C NMR (75 MHz,
CDCl3, d, ppm): 34.6 (CH3), 120.1 (ArCH, HC‚C), 136.6
(ArCH, HC‚N), 148.3 (ArC–NO2). EIMS m/z (%): 127
(M+, 100), 111 (10.6), 97 (5.4), 81 (12.4), 69 (12.7), 54 (11.1),
42 (78.5). Anal. Calcd. for C4H5N3O2: C, 37.80; H, 3.97; N,
33.06. Found C, 38.01; H, 3.93; N, 32.96.
4.5. Antimicrobial assays
Antibacterial activity: In the present study, synthetic com-
pound (I) was monitored for antibacterial activities against
Gram positive and Gram negative bacteria. All the bacterial
isolates were checked for purity and maintained on nutrient
agar at 4 C in refrigerator prior to use. Antibacterial activity
of the title compound (I) against pathogenic bacteria was
determined using the agar-well method. Autoclaved Muller
Hinton broth (Oxoid, Basingstoke–UK) was used to refresh
the bacterial culture, later wells were punched into Muller
Hinton Agar and 10 microlitres of culture were poured into
the wells (Perez et al., 1990). All plates were incubated at
28 ± 2 C for 24–48 h and after incubation the diameter of
the inhibition zone was measured. Gentamicin antibiotic was
used as a control agent in testing.
Antifungal activity: Test organisms for this study were
members of the 6 saprophytic fungi Penicillium sp., Aspergillus
ﬂavus, Aspergillus niger, Fusarium sp., Rhizopus, Helminthos-
porium and Neurospora, 5 dermatophytic Microsporum canis,
Microsporum gypseum, Trichophyton rubrum, Trichophyton
mentagrophytes, Trichophyton tonsurans and 6 yeasts including
C. albicans, C. albicans ATCC 0383, Saccharomyces cerevisiae,
C. glabrata, C. tropicalis, C. krusei. All the fungal isolates were
checked for purity and maintained on Sabourd Dextrose Agar
(SDA) (Oxoid, Basingstoke–UK) at 4 C in the refrigerator
until required for use. Antifungal activity of the title com-
pound against human, environmental and phyto-pathogenic
fungi was determined by using the agar-well method. Auto-
claved distilled water was used for the preparation of fungal
spore suspension and transferred aseptically into each SDA
plates (Cappuccino and Sherman, 2007). All plates were
incubated at 28 ± 2 C for 24–48 h and after incubation, the
diameter of the zone of inhibition was measured. Griseofulvin
antifungal agent was used as a control.
4.7. Minimum inhibitory concentration (MIC)
Minimum inhibitory concentration (MIC) of the synthetic
compound (I) was determined by the Micro broth dilution
method using 96-well microtitre plate (Samie et al., 2005).
Stock solution of 10 mg/mL was prepared in chloroform,
two fold serial dilutions were made in 100 lL broth (Oxoid,
Basingstoke–UK) and subsequently 10 lL of 2 h old refresh
culture matched with 0.5 Mac Farland index was inoculated
into each well. One well served as antibiotic and antifungal
control while others served as culture control to check MIC.
Microtitre plate was incubated for 24 h at 37 C. The MIC
showed no visible growth.Acknowledgements
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